Press Releases
WILMINGTON, Del., June 24, 2025, – Ashland has launched additional viatel™ bioresorbable polymer grades with higher molecular weights and crystallinity that provide outstanding performance in medical device and dermal filler applications. This line extension is designed to expand our solution offering of lactide, glycolide and caprolactone copolymers for biomedical applications, specifically in the fabrication of degradable medical devices, regenerative medicine scaffolds and aesthetic medicine spaces.
Sales of $479 million, down 17 percent from the prior-year quarter Previously announced carboxymethylcellulose (CMC), methylcellulose (MC), nutraceuticals and Avoca portfolio optimization initiatives (collectively, “Portfolio Optimization”) reduced overall sales by approximately $67 million or 12
WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company’s live webcast with securities analysts will include an executive summary
Globalize strategy creates meaningful change for customers’ organic growth opportunities WILMINGTON, DE – April 3, 2025 – Ashland Global Holdings Inc. (NYSE: ASH) has launched collapeptyl™, a groundbreaking, biofunctional innovation in collagen science that addresses growing consumer demands for
WILMINGTON, Del., April 1, 2025 - In 2024 ASH celebrated 100-years of transformative change. Today, Ashland has laid the groundwork for a new kind of innovation, laser-focused on the future, driven by sustainable platform technologies and groundbreaking scientific discoveries.